The German Breast Group - Developmental Therapeutics Review - Q1 2011

Global Markets Direct, March 2011, Pages: 63

The German Breast Group – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “The German Breast Group – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by The German Breast Group.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The German Breast Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of The German Breast Group’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in The German Breast Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate The German Breast Group’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of The German Breast Group in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with The German Breast Group.
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
The German Breast Group Snapshot
The German Breast Group Overview
Key Information
Key Facts
The German Breast Group – Research and Development Overview
Key Therapeutic Areas
The German Breast Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The German Breast Group – Pipeline Products Glance
The German Breast Group – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The German Breast Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
The German Breast Group – Drug Profiles
Adriamycin (Doxorubicin) + Docetaxel + Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Adriamycin (Doxorubicin) + Docetaxel + Tamoxifen + cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Capecitabine
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Avastin + Xeloda
Product Description
Mechanism of Action
R&D Progress
epirubicin + cyclophosphamide + docetaxel
Product Description
Mechanism of Action
R&D Progress
epirubicin + cyclophosphamide + docetaxel + bevacizumab
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Docetaxel + Capecitabine
Product Description
Mechanism of Action
R&D Progress
epirubicin + cyclophosphamide + docetaxel + lapatinib
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Docetaxel + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Docetaxel + Trastuzumab
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Taxol + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Ibandronate + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Nab-Paclitaxel + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Avastin + Xeloda
Product Description
Mechanism of Action
R&D Progress
paclitaxel + everolimus
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + RAD001
Product Description
Mechanism of Action
R&D Progress
Trastuzumab + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Zoledronic Acid
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Docetaxel + Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Nexavar + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Paclitaxel +Trastuzumab
Product Description
Mechanism of Action
R&D Progress
Goserelin
Product Description
Mechanism of Action
R&D Progress
Nexavar (Sorafenib)
Product Description
Mechanism of Action
R&D Progress
RAD001
Product Description
Mechanism of Action
R&D Progress
The German Breast Group – Pipeline Analysis
The German Breast Group – Pipeline Products by Therapeutic Class
The German Breast Group - Pipeline Products By Target
The German Breast Group – Pipeline Products by Route of Administration
The German Breast Group – Pipeline Products by Molecule Type
The German Breast Group – Recent Pipeline Updates
The German Breast Group - Dormant Projects
The German Breast Group – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Germany Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
• Germany Electronic Cigarettes Market 2011-2015
• Drug Delivery Devices Market Outlook in Germany to 2017- Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
• Germany Ophthalmic Devices Market Outlook to 2017 - Vision Care, Ophthalmic Diagnostic Equipment, Cataract, Refractive, Vitreo Retinal and Glaucoma Surgery Devices
• Germany In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Future Horizons in the Germany Transfusion Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Typing, Grouping and Screening Tests by Market Segment
• ENT Devices Market Outlook in Germany to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
• Future Horizons in the German Immunodiagnostics Market: Supplier Shares and Sales Forecasts for 100 Chemistry, TDM, Endocrine, Cancer, Immunoprotein and Abused Drug Tests by Market Segment
• Future Horizons in the German Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment
• Future Horizons in the German Hematology and Flow Cytometry Market: Supplier Shares and Sales Forecasts for 40 Tests by Market Segment